A recent publication reported that Systolic Blood Pressure Intervention Trial participants with 10-year cardiovascular disease risk less than 11.5% derived more harm than benefit from intensive treatment. The authors consider that serious adverse events (SAEs) are of equal importance to that of either all-cause death or the primary composite outcome (myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes). Under this premise, one death would correspond to 2.7 SAEs and a primary outcome to 1.8 SAEs overall, and to be between 6 and 18 times as important as an SAE in the intensive treatment group. In our opinion, patient utility should be considered when clinical decisions are made for the treatment of hypertension.

最近的一份出版物报道，患有10年心血管疾病风险低于11.5％的收缩压干预试验参与者所遭受的伤害大于受益于强化治疗的风险。作者认为，严重不良事件（SAE）与全因死亡或主要复合结果（心肌梗塞，其他急性冠状动脉综合征，中风，心力衰竭或心血管原因死亡）同等重要。在此前提下，一次死亡相当于2.7例SAE，主要结果相当于1.8例SAE，在强化治疗组中，其重要性是SAE的6至18倍。我们认为，在做出治疗高血压的临床决策时应考虑患者的效用。